Cover Image
市場調查報告書

EpiCast Report:老年性黃斑部病變的流行病學預測

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 312373
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:老年性黃斑部病變的流行病學預測 EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026
出版日期: 2017年11月01日 內容資訊: 英文 38 Pages
簡介

老年性黃斑部病變(AMD),是由於在視網膜擔任中心視野之黃斑逐步劣化所引起,進行性的眼科疾病。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的老年性黃斑部病變(AMD)的患病數量,預計從2013年的55,770,401件,今後10年達到66,069,370件,增加18.5%。

本報告提供全球主要7個國家的老年性黃斑部病變(AMD)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • 主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
  • AMD的流行病學預測
    • AMD的整體患病數量
    • AMD的整體患病數量:各年齡
    • AMD的整體患病數量:性別
    • AMD的整體得病率:年齡標準化
    • AMD的整體患病數量:各階段
    • AMD後期的整體患病數量:各子類型
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER170-17

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (NEI, 2015; NHS, 2015). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Early AMD is characterized by the presence of drusen (tiny yellow or white accumulations of extracellular material at the back of the eye) and/or focal pigmentary changes, both of which precede significant visual loss.

The total prevalent cases of AMD in the 7MM will increase from in the 7MM will increase from around 71 million cases in 2016 to almost 83 millioncases in 2026, at an Annual Growth Rate(AGR) of about 1.6% over the forecast period. Throughout the forecast period,Japan will have the highest number of total prevalent cases of AMD, followed by Italy.The total prevalent cases of AMD in Japan and Italy combined will make upapproximately39% of the total prevalent cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.

The diagnosed incident cases of AMD in the 7MM will increase from around 11.2 million cases in 2016 to nearly 13 million cases in 2026, at an AGR of almost 1.5%. Throughout the forecast period,Japan will have the highest number of diagnosed incident cases of AMD, followed by Italy.The diagnosed incident cases of AMD in Japan and Italy combined will make up approximately40% of the diagnosed incident cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of AMD in the 7MM to the changing population demographics in the respective markets.

The report "EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).The reportalso includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets.

Scope

  • The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors and global trends of AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets. GlobalData epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older). Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen (≥125 µm) segmented by sex and age (ages 50 years and older) in these markets.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The AMD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD population by type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Age-Related Macular Degeneration: Executive Summary 5

  • 2.1 Related Reports 7
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 12
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 14
    • 3.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 18
  • 3.5 Epidemiological Forecast for AMD (2016-2026) 20
    • 3.5.1 Total Prevalent Cases of AMD 20
    • 3.5.2 Age-Specific Total Prevalent Cases of AMD 20
    • 3.5.3 Sex-Specific Total Prevalent Cases of AMD 22
    • 3.5.4 Total Prevalent Cases of Early AMD 22
    • 3.5.5 Total Prevalent Cases of Late AMD 23
    • 3.5.6 Total Prevalent Cases of Late Dry AMD 24
    • 3.5.7 Total Prevalent Cases of Late Wet AMD 24
    • 3.5.8 Total Prevalent Cases of Large Drusen 25
    • 3.5.9 Diagnosed Incident Cases of AMD 26
    • 3.5.10 Age-Specific Diagnosed Incident Cases of AMD 27
    • 3.5.11 Sex-Specific Diagnosed Incident Cases of AMD 27
    • 3.5.12 Diagnosed Incident Cases of Early AMD 28
    • 3.5.13 Diagnosed Incident Cases of Late AMD 29
    • 3.5.14 Diagnosed Incident Cases of Late Dry AMD 30
    • 3.5.15 Diagnosed Incident Cases of Late Wet AMD 30
    • 3.5.16 Diagnosed Incident Cases of Large Drusen 31
  • 3.6 Discussion 32
    • 3.6.1 Epidemiological Forecast Insight 32
    • 3.6.2 Limitations of the Analysis 32
    • 3.6.3 Strengths of the Analysis 33

4 Appendix 34

  • 4.1 Bibliography 34
  • 4.2 About the Authors 36
    • 4.2.1 Epidemiologist 36
    • 4.2.2 Reviewers 36
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 37
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 37
  • 4.3 About GlobalData 38
  • 4.4 Contact Us 38
  • 4.5 Disclaimer 38

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbid Conditions Associated with AMD 9
  • Table 2: Classification of AMD 11
  • Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 20
  • Table 4: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 23
  • Table 5: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 23
  • Table 6: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 24
  • Table 7: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages ≥50 Years, Selected Years 2016-2026 25
  • Table 8: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 25
  • Table 9: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 26
  • Table 10: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 29
  • Table 11: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 29
  • Table 12: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 30
  • Table 13: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 31
  • Table 14: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 31

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026 6
  • Figure 2: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026 7
  • Figure 3: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages ≥50 Years, 2016 10
  • Figure 4: 7MM, Sources Used, Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 12
  • Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 13
  • Figure 6: 7MM, Age-Specific Total Prevalent Cases of AMD, Both Sexes, N, 2016 21
  • Figure 7: 7MM, Sex-Specific Total Prevalent Cases of AMD, Ages ≥50 Years, N, 2016 22
  • Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of AMD, Both Sexes, N, 2016 27
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of AMD, Ages ≥50 Years, N, 2016 28
Back to Top